Form 4: Director Granted Stock Options at Pasithea Therapeutics

Pasithea Therapeutics Corp. reports a Form 4 filing detailing the grant of stock options to Director Emer Leahy.

Summary

• Emer Leahy, a Director at Pasithea Therapeutics Corp., was granted stock options on May 1, 2026.
• The options have an exercise price of $0.84 per share.
• A total of 152,783 stock options were granted.
• These options are exercisable starting May 1, 2026, and expire on April 30, 2036.
• The underlying securities are 152,783 shares of Pasithea Therapeutics Corp. common stock.
• The grant was made under the Issuer's 2023 Stock Incentive Plan.
• The options will vest in full on the one-year anniversary of the grant date, provided the reporting person remains a director.
• Vesting will also occur immediately upon a Change in Control as defined by the plan.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral, as it reports a standard compensation event for a director rather than providing new financial or strategic information about the company's performance.

Positives

• Director Emer Leahy has been granted stock options, aligning her interests with shareholders.
• The stock options vest upon a Change in Control, providing potential upside for the director in such an event.
• The grant is part of the company's 2023 Stock Incentive Plan, indicating a structured approach to executive compensation.

Negatives

• No specific financial performance metrics are detailed in this filing, making it difficult to assess the immediate impact on the company's financial health.
• The value of the stock options is contingent on future stock price performance.

Risks

• The value of the granted stock options is subject to market volatility and the company's future stock performance.
• If Emer Leahy ceases to be a director before the vesting date, the options may not vest, unless a Change in Control occurs.

Future Outlook

The filing itself does not contain forward-looking statements or guidance regarding the company's financial performance. It solely reports a transaction related to executive compensation.

Industry Context

StockSavvy.ai notes that the issuance of stock options to directors is a common practice in the biotechnology and pharmaceutical sectors, aiming to incentivize long-term performance and align executive interests with shareholder value. This filing is typical for a company at this stage of development.

Related Party Transactions

• The grant of stock options to Director Emer Leahy is a related party transaction, as it involves a company insider.

Stakeholder Impact

• Shareholders: The grant of options aligns the director's interests with shareholders, potentially encouraging actions that increase stock value. However, it also represents potential future dilution if options are exercised.
• Employees: This filing does not directly impact employees, but it is part of the broader compensation structure that can influence morale and retention.
• Management: Reinforces the compensation structure for key leadership.

Next Steps

• The stock options will vest on May 1, 2027, provided Emer Leahy remains a director.
• The options will fully vest upon a Change in Control event.

Key Dates

Keywords

Form 4, SEC Filing, Pasithea Therapeutics Corp., KTTA, Stock Options, Director Compensation, Beneficial Ownership, Emer Leahy, Stock Incentive Plan